Snowflake Inc. – Consensus Indicates Potential 23.4% Upside

Snowflake Inc. with ticker code (SNOW) now have 32 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 530 and 125 and has a mean target at 221.56. Now with the previous closing price of 179.48 this would indicate that there is a potential upside of 23.4%. The 50 day MA is 160.63 and the 200 moving average now moves to 215.81. The market capitalisation for the company is $59,863m. Visit the company website at: https://www.snowflake.com

The potential market cap would be $73,898m based on the market concensus.

Snowflake Inc. provides a cloud-based data platform in the United States and internationally. The company’s platform offers Data Cloud, which enables customers to consolidate data into a single source of truth to drive meaningful business insights, build data-driven applications, and share data. Its platform is used by various organizations of sizes in a range of industries. The company was formerly known as Snowflake Computing, Inc. and changed its name to Snowflake Inc. in April 2019. Snowflake Inc. was incorporated in 2012 and is based in Bozeman, Montana.

Share on:

Written by: Charlotte Edwards

Find more news, interviews, share price & company profile here for:

Latest Company News

JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

Surface Transforms appoints Paul Marr as Non-Executive Director

Surface Transforms has appointed Paul Marr to its Board as Non-Executive Director. Marr brings over 40 years of global automotive manufacturing and operational leadership experience, including senior roles at General Motors and other international groups.

Avation signs 12-year lease for ATR 72-600 with Cambodian airline

Avation has agreed a twelve-year lease with a Cambodian carrier for a new ATR 72-600, the second of ten aircraft ordered in 2024. Delivery is scheduled for February 2026.

Tern Plc delivers stronger interim results with reduced loss and portfolio growth

Tern Plc reported improved interim results for the six months to 30 June 2025, with a 64% reduction in loss, disciplined cost control, and a new strategic investment in Sure Ventures plc. The company also strengthened portfolio support through successful fundraises.